Caractéristiques de la population ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; FISH, fluorescence in situ hybridization; H, trastuzumab; IHC, immunohistochemistry; P, pertuzumab; PR, progesterone receptor; T, docetaxel; TCH, docetaxel/carboplatin/trastuzumab FEC+H+P x3  T+H+P x3 n = 72 FEC x3  T+H+P x3 n = 75 TCH+P x6 n = 76 Age médian, années (range)49.0 (27‒77)49.0 (24‒75)50.0 (30‒81) ECOG PS 0, n (%) 1, n (%) 65 (91.5) 6 (8.5) 66 (88.0) 9 (12.0) 67 (88.2) 9 (11.8) RE et/ou RP positifs, n (%) RE et RP negatifs, n (%) 39 (53.4) 34 (46.6) 35 (46.7) 40 (53.3) 40 (51.9) 37 (48.1) Présentation initiale, n (%) Opérables Localement avancés Inflammatoire 53 (72.6) 15 (20.5) 5 (6.8) 54 (72.0) 17 (22.7) 4 (5.3) 49 (63.6) 24 (31.2) 4 (5.2) HER2 IHC 0 et 1+, n (%) 2+, n (%) 3+, n (%) 1 (1.4) 5 (6.8) 67 (91.8) 0 (0.0) 1 (1.3) 74 (98.7) 0 (0.0) 2 (2.6) 75 (97.4) HER2 FISH-positifs, n (%) FISH-negatifs n (%) Inconnu, n (%) 69 (94.5) 0 (0.0) 4 (5.5) 69 (92.0) 1 (1.3) 5 (6.7) 73 (94.8) 2 (2.6) 2 (2.6)